ATE513831T1 - Pyridinä3,4-büpyrazinone - Google Patents

Pyridinä3,4-büpyrazinone

Info

Publication number
ATE513831T1
ATE513831T1 AT07734320T AT07734320T ATE513831T1 AT E513831 T1 ATE513831 T1 AT E513831T1 AT 07734320 T AT07734320 T AT 07734320T AT 07734320 T AT07734320 T AT 07734320T AT E513831 T1 ATE513831 T1 AT E513831T1
Authority
AT
Austria
Prior art keywords
pyridinä3
büpyrazinone
Prior art date
Application number
AT07734320T
Other languages
German (de)
English (en)
Inventor
Robert Hughes
Andrew Bell
David Brown
Dafydd Owen
Michael Palmer
Christopher Phillips
Yvette Fobian
John Freskos
Steven Heasley
Eric Jacobsen
Todd Maddux
Brent Mischke
John Molyneaux
Joseph Moon
Donald ROGIER
Michael Tollefson
John Walker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE513831T1 publication Critical patent/ATE513831T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
AT07734320T 2006-04-21 2007-04-10 Pyridinä3,4-büpyrazinone ATE513831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21
PCT/IB2007/001001 WO2007122466A1 (en) 2006-04-21 2007-04-10 Pyridine[3,4-b]pyrazinones

Publications (1)

Publication Number Publication Date
ATE513831T1 true ATE513831T1 (de) 2011-07-15

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07734320T ATE513831T1 (de) 2006-04-21 2007-04-10 Pyridinä3,4-büpyrazinone

Country Status (41)

Country Link
US (1) US7902195B2 (enExample)
EP (1) EP2013208B1 (enExample)
JP (1) JP4436892B2 (enExample)
KR (1) KR101061328B1 (enExample)
CN (1) CN101454320B (enExample)
AP (1) AP2408A (enExample)
AR (1) AR060525A1 (enExample)
AT (1) ATE513831T1 (enExample)
AU (1) AU2007242555B2 (enExample)
BR (1) BRPI0710658A2 (enExample)
CA (1) CA2649775C (enExample)
CR (1) CR10327A (enExample)
CU (1) CU23777B7 (enExample)
CY (1) CY1111739T1 (enExample)
DK (1) DK2013208T3 (enExample)
DO (1) DOP2007000080A (enExample)
EA (1) EA014919B1 (enExample)
EC (1) ECSP088803A (enExample)
ES (1) ES2366239T3 (enExample)
GT (1) GT200700035A (enExample)
HR (1) HRP20110539T1 (enExample)
IL (1) IL194591A (enExample)
MA (1) MA30352B1 (enExample)
ME (1) MEP23808A (enExample)
MX (1) MX2008012456A (enExample)
MY (1) MY148583A (enExample)
NL (1) NL2000583C2 (enExample)
NO (1) NO20084129L (enExample)
NZ (1) NZ571540A (enExample)
PA (1) PA8724201A1 (enExample)
PE (1) PE20080192A1 (enExample)
PL (1) PL2013208T3 (enExample)
RS (2) RS51885B (enExample)
SI (1) SI2013208T1 (enExample)
SV (1) SV2008003074A (enExample)
TN (1) TNSN08408A1 (enExample)
TW (1) TWI337609B (enExample)
UA (1) UA92637C2 (enExample)
UY (1) UY30291A1 (enExample)
WO (1) WO2007122466A1 (enExample)
ZA (1) ZA200808283B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2013208T3 (da) 2006-04-21 2011-08-15 Pfizer Prod Inc Pyridin[3,4-B]pyrazinoner
JP2010512414A (ja) * 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
AU2009221213B2 (en) * 2008-03-05 2014-02-27 Merck Patent Gmbh Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
EP2351748A4 (en) * 2008-10-09 2012-03-21 Kyorin Seiyaku Kk ISOCHINOLINE DERIVATIVES AND THESE PDE INHIBITORS CONTAINING ACTIVE SUBSTANCE
NZ599549A (en) * 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
EA026074B1 (ru) 2010-10-15 2017-02-28 Джилид Сайэнс, Инк. Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CA2893256A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
WO2015049616A1 (en) 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
BR112016022519A8 (pt) 2014-04-01 2018-03-06 Pfizer cromeno e 1,1a,2,7b-tetra-hidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gama-secretase
JP6111002B1 (ja) 2014-04-10 2017-04-05 ファイザー・インク ２−アミノ−６−メチル−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル−１，３−チアゾール−４−イルアミド
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
DK3310784T3 (da) 2015-06-17 2020-11-09 Pfizer Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
KR102148587B1 (ko) 2016-02-23 2020-08-26 화이자 인코포레이티드 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물
PL3478679T3 (pl) 2016-07-01 2021-10-25 Pfizer Inc. Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych
FI3642202T3 (fi) 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
CN111182898B (zh) * 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
EP3768669B1 (en) 2018-03-23 2023-01-25 Pfizer Inc. Piperazine azaspiro derivaves
EP4297868A4 (en) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. USE OF APREPITANT TO TREAT ALZHEIMER'S
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
AU2024413926A1 (en) 2023-12-29 2026-07-09 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
WO2025160132A1 (en) * 2024-01-23 2025-07-31 Maplight Therapeutics, Inc. Gpr6 inverse agonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
HU221425B (en) 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
TW274550B (enExample) 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) * 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidine and naphthyridine derivatives
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
US7476665B2 (en) 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
CA2593005A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
CA2620414A1 (en) 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DK2013208T3 (da) 2006-04-21 2011-08-15 Pfizer Prod Inc Pyridin[3,4-B]pyrazinoner

Also Published As

Publication number Publication date
RS20080484A (sr) 2009-07-15
US7902195B2 (en) 2011-03-08
DK2013208T3 (da) 2011-08-15
ZA200808283B (en) 2009-11-25
CY1111739T1 (el) 2015-10-07
PE20080192A1 (es) 2008-03-01
JP4436892B2 (ja) 2010-03-24
CR10327A (es) 2008-10-21
NO20084129L (no) 2008-10-29
EP2013208A1 (en) 2009-01-14
AR060525A1 (es) 2008-06-25
HK1133875A1 (en) 2010-04-09
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
EA200801998A1 (ru) 2009-04-28
EA014919B1 (ru) 2011-04-29
IL194591A (en) 2012-07-31
RS51885B (sr) 2012-02-29
AU2007242555A1 (en) 2007-11-01
US20070249615A1 (en) 2007-10-25
AP2008004640A0 (en) 2008-10-31
MEP23808A (en) 2010-06-10
GT200700035A (es) 2008-02-05
CU23777B7 (es) 2012-02-15
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
PL2013208T3 (pl) 2011-10-31
MY148583A (en) 2013-04-30
CU20080194A7 (es) 2011-03-21
UY30291A1 (es) 2007-11-30
NZ571540A (en) 2010-10-29
HRP20110539T1 (hr) 2011-08-31
CA2649775A1 (en) 2007-11-01
TW200808794A (en) 2008-02-16
TNSN08408A1 (fr) 2010-04-14
BRPI0710658A2 (pt) 2011-08-16
NL2000583A1 (nl) 2007-10-23
KR20080110930A (ko) 2008-12-19
SV2008003074A (es) 2010-01-12
EP2013208B1 (en) 2011-06-22
WO2007122466A1 (en) 2007-11-01
ECSP088803A (es) 2008-11-27
MX2008012456A (es) 2008-10-10
TWI337609B (en) 2011-02-21
PA8724201A1 (es) 2009-08-26
JP2009534368A (ja) 2009-09-24
KR101061328B1 (ko) 2011-08-31
MA30352B1 (fr) 2009-04-01
CN101454320A (zh) 2009-06-10
DOP2007000080A (es) 2007-11-15
ES2366239T3 (es) 2011-10-18
CA2649775C (en) 2011-05-31
AU2007242555B2 (en) 2010-12-16
SI2013208T1 (sl) 2011-09-30

Similar Documents

Publication Publication Date Title
FR2909857B1 (fr) Endovalve.
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
DE602006004717D1 (de) Kapselperforationsmodul
AT504580A3 (de) Scan-einrichtung
DE602007000258D1 (de) Kassetteneinspannmechanismus
DE602007001280D1 (de) Getränkeextraktor
DE602006020192D1 (de) Riemenscheibenanorndung
DE602007001098D1 (de) Spindelmäheinheit
CR10353A (es) Nuevos compuestos.
DE502007001629D1 (de) Rfahren
BRPI0717939A2 (pt) Aminometil-4-imidazóis
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007000501D1 (de) Breitbandrichtkoppler
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
DE502007000361D1 (de) Stanznieteinheit
DE602007000333D1 (de) Napfbefestigungsvorrichtung
DE602006019150D1 (de) Riemenscheibenanorndung
DE602007009334D1 (de) Garnerwärmungsvorrichtung
DE502007001652D1 (de) Notöltank
DE502007006319D1 (de) Staubabsaugadaptervorrichtung
DE602006016174D1 (de) Blisterverpackungsverfahren
BRPI0719956A2 (pt) Radiofluoração
DE102006045567A8 (de) Crimpstabilisierung
DE602006015328D1 (de) Abtastfehlerkompensation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2013208

Country of ref document: EP